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The relationship between cardiovascular disease and Glu298Asp polymorphism of nitric 
oxide synthase (eNOS) gene in vascular endothelial cells is controversial due to conﬂict-
ing results.  To demonstrate the effects of Glu298Asp polymorphism of the eNOS gene 
on eNOS gene expression by excluding the effects of various confounding factors, eNOS 
mRNA and protein expressions were measured using cultured human umbilical vein 
endothelial cells (HUVECs) according to genotypes of Glu298Asp polymorphism of the 
eNOS gene.  eNOS mRNA expression was measured by real-time PCR/reverse trasn-
scription-PCR.  eNOS protein expression was measured by an immunoassay method. 
HUVECs with Glu298Asp tended to show higher eNOS mRNA and protein expressions 
than those with Glu298Glu, but the difference was not signiﬁcant.  These results sug-
gest that the genotypic difference of Glu298Glu and Glu298Asp has no effect on eNOS 
mRNA and protein expressions.
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Nitric oxide produced from vascular endothelial 
cells is synthesized from L-arginine by the func-
tions of nitric oxide synthase (eNOS).  Major 
functions of vascular endothelial cell-derived NO 
include relaxant and antiproliferative effects on 
vascular smooth-muscle cells, antiaggregant ef-
fects on the platelets, and inhibitory effects on ad-
hesion of leukocytes to vascular endothelial cells 
(Kader et al., 2000; Ozaki et al., 2002).  In addi-
tion, the relationship between NO production in 
vascular endothelial cells and various pathologic 
conditions such as inﬂammatory disease, hyper-
tension, and coronary artery disease has been re-
ported.
 The eNOS gene is located on chromosome 7 
(7q35-36), spans 21 kb, and consists of 26 exons 
(Marsden et al., 1993).  Among several reported 
polymorphisms of the eNOS gene, the involve-
ment of Glu298Asp polymorphism (glutamic acid 
to aspartic acid substitution at codon 298) in coro-
nary artery disease and essential hypertension has 
been discussed (Miyamoto et al., 1998; Kato et al., 
1999; Shoji et al., 2000; Benjaﬁeld et al., 2000; 
Colombo et al., 2002).  The conﬂicting results are 
considered to be caused by confounding factors 
such as differences in the genetic backgrounds of 
study populations and various environmental fac-
tors.
 It is important to experimentally investigate 
the functional effects of Glu298Asp polymor-
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phism on eNOS gene expression by excluding 
these confounding factors.  Thus, we identified 
Glu298Asp polymorphism using cultured human 
vascular endothelial cells, and investigated the 
functional effects of Glu298Asp polymorphism 
on eNOS mRNA and protein expressions.
 
Materials and Methods
Ethics
This study was reviewed and approved by the 
Ethical Committee of the Faculty of Medicine, 
Tottori University.  Biomaterials (human umbili-
cal cords) were collected after obtaining informed 
consent from the pregnant women.
Cell culture
Human umbilical cords were aseptically obtained 
immediately after delivery, and human umbilical 
vein endothelial cells (HUVECs) were collected 
by enzyme treatment with 0.5 g/L collagenase 
type IV (Wako Pure Chemical, Osaka, Japan). 
The collected HUVECs were plated onto gelatin-
coated plastic culture dishes, and were statically 
cultured in a CO2 incubator (5% CO2 in 95% 
humidiﬁed air).  An Endothelial Cell Growth Me-
dium 2 Kit (Promo Cell, Heidelberg, Germany) 
was used as the growth medium.  The kit includes 
the following:  endothelial cell basal medium, 2% 
fetal calf serum, 5.0 ng/mL epidermal growth 
factor, 0.2 µg/mL hydrocortisone, 5.0 ng/mL vas-
cular endothelial growth factor, 10 ng/mL basic 
ﬁbroblast factor, 20 ng/mL R3 insulin-like growth 
factor-1, 1 µg/mL ascorbic acid, 22.5 µg/mL 
heparin, 50 ng/mL amphotericin B and 50 µg/mL 
gentamicin.
Identiﬁcation of Glu298Asp polymorphism
DNA was extracted from umbilical cord tissue 
using an automatic nucleic acid extraction instru-
ment (MFX-2000, Toyobo, Osaka), and a PCR 
with confronting 2-pair primers for polymorphism 
(PCR-CTPP) method (Hamajima et al., 2000) was 
performed using 4 primers (primer 1:  5'-CAT 
GAG GCT CAG CCC CAG AAC-3', primer 2: 
5'-AGT CAA TCC CTT TGG TGC TCAC-3', 
primer 3:  5'-GAA GGA AGA GTT CTG GGG 
GA-3', primer 4:  5'-GCT GCA GGC CCC AGA 
TGA G-3').  In the primary cultures of 29 cases, 
polymorphisms were identified.  As a result, 26 
cases with the Glu298Glu genotype and 3 cases 
with the Glu298Asp genotype were identiﬁed.
Comparative quantiﬁcation of eNOS gene 
mRNA expression
mRNA was extracted from HUVECs using ISO-
GEN (Nippon Gene, Toyama, Japan).  eNOS 
mRNA expression was measured by a real-time 
PCR/reverse transcription-PCR method.  A Fast 
Start DNA Master SYBER Green I Kit (Roche 
Diagnostics, Tokyo, Japan) was used as a reagent, 
and the primers used were as follows:  5'-CAT 
GAG GCT CAG CCC CAG AAC-3' and 5'-AGT 
CAA TCC CTT TGG TGC TCAC-3'.  A Takara 
PCR Thermal Cycler (Takara Bio, Ootsu, Japan) 
was used for cDNA synthesis under the following 
reaction conditions: annealing at 30˚C for 10 min, 
reverse transcription at 42˚C for 15 min, and inac-
tivation of reverse transcriptase at 99˚C for 5 min. 
A LightCycler (Roche Diagnostics) was used for 
real-time PCR.  PCR was performed under the 
following conditions:  after denaturing at 95˚C 
for 10 min, 50 cycles of denaturing at 95˚C for 15 
s, annealing at 60˚C for 5 s, and extension at 72˚
C for 10 s with a temperature transition rate of 20
˚C/s.  Fluorescence was recorded following the 
extension reaction stages of each cycle.  β-actin 
gene mRNA expression was also measured for 
comparative quantiﬁcation, and eNOS and β-actin 
mRNA expressions were quantiﬁed comparatively 
by calculating the ratio between them.  The prim-
ers used for β-actin gene were as follows:  5'-CGT 
GAC ATT AAG GAG AAG CTG TGC-3' and 
5'-GTC ATA CTC CTG CTT GOT GAT CCA-3'.
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Quantiﬁcation of eNOS protein expression
An immunoassay method by a Human eNOS 
Immunoassay Kit (R&D Systems, Minneapolis, 
MN) was used to measure the eNOS protein ex-
pression.  In brief, cells were trypsinized for col-
lection, and were precipitated by centrifugation at 
300 × g for 5 min.  Then cells were washed twice 
with phosphate-buffered saline, and after the ad-
dition of cell lysis buffer, the cell solution was 
centrifuged at 300 × g for 5 min, and the concen-
tration of eNOS protein in the supernatant was 
measured by a microplate  reader.
Experiments according to Glu298Asp geno-
types
HUVECs with the Glu298Glu or Glu298Asp 
genotype were plated onto 2 gelatin-coated 60 
mm plastic dishes, and were cultured in growth 
medium to reach confluence.  Subsequently, the 
medium was replaced with fresh growth medium, 
and 24 h later, mRNA and protein expressions 
were measured as described above.  Measurement 
was conducted on different dates using different 
HUVECs derived from 5 and 3 individuals for 
Glu298Glu and Glu298Asp genotypes, respec-
tively.
Statistical analysis
SPSS software (version 11.0J) was used for statis-
tical analysis.  Student’s t-test was used as a sta-
tistical method for comparison.  The signiﬁcance 
level was set to 5%.
Results
The effects of genotypes on eNOS mRNA and 
protein expressions are shown in Fig. 1.  eNOS 
mRNA expression tended to be higher in HU-
VECs with the Glu298Asp genotype than in 
those with Glu298Glu (Fig. 1A), but the differ-
ence was not significant.  Also, eNOS protein 
expression tended to be higher in HUVECs with 
the Glu298Asp genotype than in those with 
Glu298Glu (Fig. 1B), but the difference was not 
signiﬁcant.
Discussion
To reveal the effects of Glu298Asp polymorphism 
of the eNOS gene on eNOS mRNA and protein 
expressions, eNOS mRNA and protein expres-
sions were measured using HUVECs with the 
Glu298Glu or Glu298Asp genotype.  Both eNOS 
mRNA and protein expressions tended to be 
higher in HUVECs with Glu298Asp than in those 
with Glu298Glu, but the difference was not sig-
niﬁcant.
 Mainly in case-control studies, the relation-
ship between the Glu298Asp polymorphism of 
the eNOS gene and cardiovascular disease is 
controversial due to conﬂicting results (Miyamoto 
Fig. 1.  eNOS mRNA expression (A) and protein concen-
trations (B) according to genotypes of eNOS polymor-
phism Glu298Asp in exon 7.  Results are expressed as 
means (SE; bars).  Values for eNOS mRNA expression (A) 
are given as the ratio of the amounts of eNOS and β-actin 
mRNA expression measured by real time PCR/reverse 
transcription-PCR.  Values for eNOS protein (B) are mea-
sured by immunoassay method.  Measurement was con-
ducted on different dates using different HUVECs derived 
from 5 and 3 individuals for Glu298Glu and Glu298Asp 
genotypes, respectively.
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et al., 1998; Kato et al., 1999; Shoji et al., 2000; 
Benjaﬁeld et al., 2000; Colombo et al., 2002).  We 
conducted a cohort study on the relationship be-
tween the Glu298Asp polymorphism of the eNOS 
gene and hypertension in Japanese, but found no 
relationship (Kishimoto et al., 2004).
 Also, there are several studies on the effects 
of the eNOS Glu298Asp genotype on the func-
tions of the circulatory system.  Schneider et al. 
(2000) investigated the dilation reaction of the 
forearm artery by administering acetylcholine 
to 80 patients, and reported no difference due to 
the eNOS Glu298Asp polymorphism.  Jesung et 
al. measured plasma nitric oxide levels derived 
from vascular endothelial cells, and reported no 
difference due to the eNOS Glu298Asp polymor-
phism.  Our study supports these results, showing 
no effects of the Glu298Asp polymorphism of the 
eNOS gene on the circulatory system.
 This study was limited by the unavailability of 
HUVECs with the homozygotic Asp298Asp geno-
type.  Our cohort study included 85.3% Glu298Glu, 
14.0% Glu298Asp and 0.7% Asp298Asp (n = 2,042). 
It is considered necessary to obtain HUVECs 
with the homozygotic Asp298Asp genotype by 
increasing the sample size in the future.
 In conclusion, the results of this study sug-
gest the possibility that the Glu298Glu and 
Glu298Asp polymorphisms of the eNOS gene 
have no effect on eNOS mRNA and protein ex-
pressions in HUVECs, and also on the circulatory 
system.
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